Company profile

Arana Therapeutics Limited, created through the merger of Peptech Limited and EvoGenix Limited in August 2007, is a biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of cancer and inflammatory diseases. The company has tapped its unique antibody technologies and revenues generated from its pioneering anti-TNF patents to build a range of therapeutic assets to address large and clinically validated markets. Arana is transitioning to a mid-stage development company as several products move from pre-clinical stages into human trials, starting with the company's lead product, ART621, a differentiated anti-TNF domain antibody construct.

Click here to access the company's market information

Presentation by Dr Steffen Nock PhD, President of US Operations

Dr Steffen Nock is the former President of Evogenix Inc., having previously participated in the foundation of Zyomyx, a biotechnology company in the San Francisco Bay area, exploiting antibody-based proteomics technologies. Zyomyx raised more than US$100M and launched several products.

Prior to this, Dr Nock held scientific research positions at Stanford University, USA, and at the University of Bayreuth, Germany.

He was one of four founders of Absalus and an executive director. On the acquisition of Absalus by EvoGenix in April 2005, Dr Nock became President of the company's US operation EvoGenix Inc. He is currently the President of Arana Therapeutics US operation.